药品不良反应评价体系是目前上市药品再评价的重要渠道；
The evaluation system of drug adverse reactions is an important channel for re-evaluation of listed drugs.
本次研究的主要目的是评价这个治疗方法的安全性。据报道出现接近于严重的不良反应也有28和90天的存活率。
The primary aim of the study was to assess safety of the treatment. Next to (serious) adverse events (s) AEs also 28 and 90 days survival rates were recorded.
目的：评价磁共振成像钆对比剂的不良反应和安全性。
Objective:To revalue the bad reaction and safety of gadopentetate dimeglumine MRI contrast.
应用推荐